Company profile
Invivyd, Inc.
NASDAQ: IVVD · Healthcare · Biotechnology
#424 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
41DFH 56DQ 15GM —SS 51
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, revenue growth (YoY) · ↓ disclosure history, listing tenure
Methodology →Revenue TTM
$55.9M
Rev growth YoY (TTM)
+52.3%
Net income (FY)
-$52.5M
Employees
122
as of 2026-08-13
Market cap
$215.7M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$53.4M$53.4M2025
Net income-$52.5M-$52.5M2025
Operating income-$55.6M-$55.6M2025
Total assets$276.9M$276.9M2025
Liabilities$35.3M$35.3M2025
Equity$241.5M$241.5M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Product100%
By geography
Not disclosed.
The read
What is Invivyd, Inc.’s revenue?
Invivyd, Inc. booked $53.4M in FY2025 revenue, growing 110% year over year — faster than most Healthcare companies we track, at a -98.2% net margin.
Peers · Healthcare
Integrated BioPharma, Inc.67BAgios Pharmaceuticals, Inc.70BQ32 Bio Inc.72BRegional Health Properties, Inc.67BApyx Medical Corporation64CProtalix BioTherapeutics, Inc.66BNeighbors
Middlesex →Key facts
CEOWilliam E. Duke Jr.
SectorHealthcare
IndustryBiotechnology
HeadquartersWaltham, MA
ExchangeNASDAQ: IVVD
Employees122
IPO date2021-08-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.